



Gennex Laboratories Limited

"AKASH GANGA" 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad - 500073. Telangana, INDIA
Tel : +91-40-67334400 (30Lines), 23746451, Fax : +91-40-67334433
Email: info@gennexlab.com | www.gennexlab.com
CIN : L24230TG1990PLCO11168

Ref: GLL/OC/2018-19/0053

Date: 14/02/2019.

To
Dy. General Manager,
Bombay Stock Exchange Ltd.,
Phiroje Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To
Asst. Manager (Listing)
The Ahmedabad Stock Exchange Ltd.,
Kamdhenu Complex, Opp.Sahajanand College,
Ahmedabad – 380 015.

To
The Secretary
The Calcutta Stock Exchange Association Ltd.,
7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject : Submission of Standalone and Consolidated Un-Audited Limited Reviewed Financial Result as per Ind-As for the 3rd Quarter and Nine Months Ended 31st December, 2018.

Reference : Security ID : GENNEX & Script Code – 531739


We enclose the Standalone and Consolidated Un-Audited Financial Results as per Ind-AS for the 3rd Quarter and Nine Months ended 31st December, 2018 of the Company together with Limited Review Report thereon pursuant to the Regulation 33(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 which was approved and taken on records by the Board of Directors at its Meeting held today i.e., 14.02.2019.

The Board Meeting commenced at 04:30 p.m. and concluded at 06 :45 p.m.

We would be obliged if you could take the above on records.

Thanking You,

Yours faithfully,
For Gennex Laboratories Ltd.,



Authorised Signatory



Encl: as above



GENNEX LABORATORIES LIMITED
 REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2018
 Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com
 CIN: L24230TG1990PLC011168


PART - I Statement of standalone Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2018							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Unaudited)	31.12.2018 (Unaudited)	31.12.2017 (Unaudited)	31.03.2018 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	1521.55	1078.16	1188.61	3544.20	3030.61	4377.88
	(b) Other operating Income	20.52	18.27	12.82	53.22	17.65	90.36
	Total Income from operations (net)	1542.07	1096.43	1201.43	3597.42	3048.26	4468.24
2	Expenses						
	(a) Cost of material consumed	939.82	696.09	719.56	2254.89	1793.31	2567.72
	(b) Purchases of stock-in-trade	0.00	2.93	13.51	2.93	13.51	30.01
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-34.60	-88.53	-3.50	-220.30	-56.23	75.42
	(d) Employee benefit expense	167.93	135.40	122.92	431.42	370.46	554.58
	(f) Finance Cost	25.65	16.45	15.23	59.09	49.44	73.11
	(g) Depreciation and amortisation expense	30.51	24.48	28.10	79.01	73.36	92.18
	(h) Other expenses	330.83	261.46	255.15	812.93	679.27	930.88
	Total expenses	1460.14	1048.28	1150.97	3419.97	2923.12	4323.9
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	81.93	48.15	50.46	177.45	125.14	144.34
4	Exceptional items	0.00	0.00	0	0.00	-1	-1
5	Profit(+)/Loss(-) before tax (3+4)	81.93	48.15	50.46	177.45	126.14	145.34
6	Taxes of earlier years	0.00	0	-19.60	0	-20.41	-61.13
7	Current Tax						-35.00
8	Deferred tax(benefit/expense)						34.37
9	Total Tax expense	0.00	0.00	-19.60	0.00	-20.41	-61.76
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	0	0	0	0	0	0
11	Profit(+)/Loss(-) for the period from continuing operation (5-9)	81.93	48.15	30.86	177.45	105.73	83.58
12	Profit(+)/Loss(-) from discontinued operations before tax	0.0	0.0	0.0	0.0	0.0	0.0
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	81.93	48.15	30.86	177.45	105.73	83.58
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	Net profit(loss) for period	81.93	48.15	30.86	177.45	105.73	83.58
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
20	Other Equity						
	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						1911.72
	(a) Basic	0.065	0.038	0.024	0.140	0.084	0.066
	(b) Diluted	0.065	0.038	0.024	0.140	0.084	0.066

NOTES to the results:

- The above standalone unaudited financial results for the nine months ended 31st December 2018 have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on February 14, 2019 and the limited review of the same has been carried out by the Auditors.
- The standalone financial results have been prepared in accordance with the India Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- Provision for Taxation & IAS-12 Deferred Tax will be made at the end of the year.
- Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- The Company has only one reportable segment namely " Bulk Drugs, Biotech Products and Intermediates".

Place: Hyderabad
Date: 14.02.2019

Jesant



For and on behalf of the Board
For Gennex Laboratories Limited
sd/-
Arihant Baid
Managing Director

LIMITED REVIEW REPORT

To
The Board of Directors,
GENNEX LABORATORIES LIMITED,
Hyderabad.

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of GENNEX LABORATORIES LIMITED ("the company") for the Quarter/ Nine Months ended 31st December, 2018 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This said statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other accounting principles generally accepted in India and has been approved by its Board of Directors. Our responsibility is to issue a report on the Financial Statement based on our review.

We conducted our review in accordance with the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion



Based on our review conducted as above and subject to the non-presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14/02/2019

For PPKG & CO
Chartered Accountants
FRN No. 009655S



Girdhari Toshniwal
(GIRDHARI LAL TOSHNIWAL)
M.No. 205140



GENNEX LABORATORIES LIMITED
 REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2018
 Tel. No. +91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com
 CIN: L24230TG1990PLC011168


PART - I Statement of Consolidated Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2018							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		(Rs. in lakhs)
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Unaudited)	31.12.2018 (Unaudited)	31.12.2017 (Unaudited)	Year ended 31.03.2018 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	1521.55	1078.16	1188.61	3544.20	3030.61	4377.88
	(b) Other operating Income	20.52	18.27	12.82	53.22	17.65	90.36
	Total Income from operations (net)	1542.07	1096.43	1201.43	3597.42	3048.26	4468.24
2	Expenses						
	(a) Cost of material consumed	939.82	696.09	719.56	2254.89	1793.31	2567.72
	(b) Purchases of stock-in-trade	0.00	2.93	13.51	2.93	13.51	30.01
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-34.60	-88.53	-3.50	-220.30	-56.23	75.42
	(d) Employee benefit expense	167.93	135.40	122.92	431.42	370.46	554.58
	(f) Finance Cost	25.65	16.45	15.23	59.09	49.44	73.11
	(g) Depreciation and amortisation expense	30.51	24.48	28.10	79.01	73.36	92.18
	(h) Other expenses	330.83	261.46	255.15	812.93	679.27	930.88
	Total expenses	1460.14	1048.28	1150.97	3419.97	2923.12	4323.9
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	81.93	48.15	50.46	177.45	125.14	144.34
4	Exceptional items	0.00	0.00	0	0.00	-1	-1
5	Profit(+)/Loss(-) before tax (3+4)	81.93	48.15	50.46	177.45	126.14	145.34
6	Taxes of earlier years	0.00	0	-19.60	0	-20.41	-61.13
7	Current Tax						-35.00
8	Deferred tax(benefit/expense)						34.37
9	Total Tax expense	0.00	0.00	-19.60	0.00	-20.41	-61.76
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	0	0	0	0	0	0
11	Profit(+)/Loss(-) for the period from continuing operation (5-9)	81.93	48.15	30.86	177.45	105.73	83.58
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	81.93	48.15	30.86	177.45	105.73	83.58
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	Net profit(loss) for period	81.93	48.15	30.86	177.45	105.73	83.58
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share) Other Equity	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						1911.72
	(a) Basic	0.065	0.038	0.024	0.140	0.084	0.066
	(b) Diluted	0.065	0.038	0.024	0.140	0.084	0.066

NOTES to the results:

- The above Consolidated unaudited financial results for the nine months ended 31st December 2018 have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on February 14, 2019 and the limited review of the same has been carried out by the Auditors.
- The consolidated financial results have been prepared in accordance with the India Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- Provision for Taxation & IAS-12 Deferred Tax will be made at the end of the year.
- Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- The Company has only one reportable segment namely " Bulk Drugs, Biotech Products and Intermediates".
- The Company is having one associate by name M/s. Deccan Remedies Limited which has not yet commenced its operations

Place: Hyderabad
Date: 14.02.2019

JeBaid



For and on behalf of the Board
For Gennex Laboratories Limited
sd/-
Arihant Baid
Managing Director

LIMITED REVIEW REPORT

To
The Board of Directors,
GENNEX LABORATORIES LIMITED,
Hyderabad.

We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of GENNEX LABORATORIES LIMITED ("the company") and its Associate for the Quarter/ Nine Months ended 31st December, 2018 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This said statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other accounting principles generally accepted in India and has been approved by its Board of Directors. Our responsibility is to issue a report on the Financial Statement based on our review.

We conducted our review in accordance with the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above and subject to the non-presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14/02/2019

For PPKG & CO
Chartered Accountants
FRN No. 009655S



Girdhari Toshniwal
(GIRDHARI LAL TOSHWAL)
M.No. 205140